AIM Rule 26 Information
The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.
About ImmuPharma
Please click below for a description of the business.
Directors and Committees
Country of Incorporation and Main Country of Operation
Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Countries of Operation: Great Britain, France, Switzerland
Registered Office
50 Broadway, London SW1H 0BL, UK
Company Reports
Latest Annual Report
|
Click on the photo for the Immupharma plc 2010 Annual Report .
Please note the file
may take It is recommended you save
|
 |
Notifications
10 June 2010
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2009, has been posted to shareholders.
The annual report is available, in electronic form, for download on the Company's website www.immupharma.com.
The Company’s Annual General Meeting will be held on 17 June 2010 at 11am at 50 Broadway, London, SW1H 0BL.
A copy of the proxy form for the AGM can be downloaded here.
Please click here for details of all notifications made in the past twelve months.
Advisers
Nominated Advisor & Broker
Panmure Gordon & Co. plc, 155 Moorgate, London EC2M 6XB, UK.
Tel +44 151 243 0963, +44 20 7459 3600
Joint Broker
Espirito Santo Investment Bank 10 Paternoster Square London
EC4M 7AL, UK. + 44 20 7456 9191
Public Relations
Buchanan Communications, 6th Floor,
45 Moorfields, London EC2Y 9AE, UK. Tel: +44 20 7466 5000
Solicitors
Bircham Dyson Bell, 50 Broadway, London SW1H 0BL, UK
Auditors
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK
Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK
Registrars
Computershare Investor Services PLC, PO Box 82, The Pavilions,
Bridgewater Road, Bristol, BS99 7NH, UK
Current Constitutional Documents
Please click below for details of current constitutional documents.
Current Constitutional Documents
Proposed Changes to Articles of Association:
Comparison of proposed new Articles with old Articles
Details of Any Other Exchanges or Trading Platforms
The Company is not listed on any other exchanges or trading platforms.
Number of Securities In Issue and Significant Shareholders
ImmuPharma has 81,091,463 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings. The company does not hold any Ordinary Shares in treasury. The Company is not aware of any interest of 2% or more in the share capital of the Company other than the persons noted below.
|
Number of Ordinary 10p shares |
% of issued share capital |
|
|
Dr Robert Zimmer |
23,056,602 |
28% |
As far as the Company is aware, the percentage of the Company's issued share capital that is not in public hands is 37%. This percentage comprises the holdings of Directors.
Details of any restrictions on the transfer of securities
There are no restrictions on the transfer of securities.
Admission Document and Circulars
There have been no circulars or similar publications within the past 12 months. Please click on the link below to access the Company's Admission Document (January 2006).
Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. Please refer to our Disclaimer.
Last Updated:14/04/201
1